Is FDG-PET a useful tool in clinical practice for diagnosing corticobasal ganglionic degeneration?

2003 ◽  
Vol 18 (10) ◽  
pp. 1175-1178 ◽  
Author(s):  
Ilse M.F. Coulier ◽  
Joeke J. de Vries ◽  
Klaus L. Leenders
Keyword(s):  
Clinical Practice ◽  
Fdg Pet ◽  
Corticobasal Ganglionic Degeneration

The CSF p-tau181/Aβ42 Ratio Offers a Good Accuracy “In Vivo” in the Differential Diagnosis of Alzheimer’s Dementia

2019 ◽  
Vol 16 (7) ◽  
pp. 587-595 ◽  
Author(s):  
Roberto Santangelo ◽  
Alessandro Dell'Edera ◽  
Arianna Sala ◽  
Giordano Cecchetti ◽  
Federico Masserini ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Clinical Diagnosis ◽  
Fdg Pet ◽  
Amyloid Β ◽  
Cost Effective ◽  
Daily Clinical Practice ◽  
Different Types ◽  
Experimental Trials ◽  
Csf Findings

Background: The incoming disease-modifying therapies against Alzheimer’s disease (AD) require reliable diagnostic markers to correctly enroll patients all over the world. CSF AD biomarkers, namely amyloid-β 42 (Aβ42), total tau (t-tau), and tau phosphorylated at threonine 181 (p-tau181), showed good diagnostic accuracy in detecting AD pathology, but their real usefulness in daily clinical practice is still a matter of debate. Therefore, further validation in complex clinical settings, that is patients with different types of dementia, is needed to uphold their future worldwide adoption. Methods: We measured CSF AD biomarkers’ concentrations in a sample of 526 patients with a clinical diagnosis of dementia (277 with AD and 249 with Other Type of Dementia, OTD). Brain FDG-PET was also considered in a subsample of 54 patients with a mismatch between the clinical diagnosis and the CSF findings. Results: A p-tau181/Aβ42 ratio higher than 0.13 showed the best diagnostic performance in differentiating AD from OTD (86% accuracy index, 74% sensitivity, 81% specificity). In cases with a mismatch between clinical diagnosis and CSF findings, brain FDG-PET partially agreed with the p-tau181/Aβ42 ratio, thus determining an increase in CSF accuracy. Conclusions: The p-tau181/Aβ42 ratio alone might reliably detect AD pathology in heterogeneous samples of patients suffering from different types of dementia. It might constitute a simple, cost-effective and reproducible in vivo proxy of AD suitable to be adopted worldwide not only in daily clinical practice but also in future experimental trials, to avoid the enrolment of misdiagnosed AD patients.

scholarly journals The role of 18F-FDG PET/CT in the management of large-vessel vasculitis: applications and limitations in clinical practice

2012 ◽  
pp. 249-254
Author(s):  
Maria V. Mattoli ◽  
Giorgio Treglia ◽  
Lucia Leccisotti ◽  
Alessandro Giordano
Keyword(s):  
Clinical Practice ◽  
Fdg Pet ◽  
False Negative ◽  
Large Vessel Vasculitis ◽  
Large Vessel ◽  
Metabolic Imaging ◽  
Small Vessel Vasculitis ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Introduction: 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) plays a key role in oncology, and it is now being used increasingly to diagnose, characterize, and monitor disease activity in inflammatory disorders, including vasculitis. Unfortunately, its role in the management of vasculitis is still not well-defined, and clinicians are often unsure how this metabolic imaging technique should be used in these diseases, although its usefulness in diagnosing large-vessel vasculitis has been clearly demonstrated. Materials and methods: We reviewed the literature about the use of PET/CT in the management of vasculitis in an attempt to identify the applications and the limitations of this technique in clinical practice. Results and discussion: Our literature review revealed that 18F-FDG PET/CT is a useful tool for diagnosing vasculitis (especially when the symptoms of the disease are non-specific); guiding biopsy procedures (areas with high glucose consumption); evaluating disease extension; and monitoring treatment responses. The main limitations of this method are the relatively low spatial resolution of the tomograph, which can lead to false-negative results in the presence of small-vessel vasculitis, and risk of false positive results, especially those related to the presence of atherosclerosis and to post-treatment vascular remodeling.

scholarly journals FDG-PET as a biomarker for early response in diffuse large B-cell lymphoma as well as in Hodgkin lymphoma? Ready for implementation in clinical practice?

Haematologica ◽  
2016 ◽  
Vol 101 (11) ◽  
pp. 1279-1283 ◽  
Author(s):  
Josée M. Zijlstra ◽  
Coreline N. Burggraaff ◽  
Marie José Kersten ◽  
Sally F. Barrington
Keyword(s):  
Clinical Practice ◽  
B Cell ◽  
Hodgkin Lymphoma ◽  
Fdg Pet ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Early Response ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Utility of Amyloid and FDG-PET in Clinical Practice: Differences Between Secondary and Tertiary Care Memory Units

2018 ◽  
Vol 63 (3) ◽  
pp. 1025-1033 ◽  
Author(s):  
Carmen Lage ◽  
Andrea Gonzalez Suarez ◽  
Ana Pozueta ◽  
Javier Riancho ◽  
Martha Kazimierczak ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Fdg Pet ◽  
Tertiary Care

scholarly journals Molecular imaging and immunotherapy

2020 ◽  
Vol 35 (1_suppl) ◽  
pp. 37-41
Author(s):  
Laura Evangelista
Keyword(s):  
Computed Tomography ◽  
Lung Cancer ◽  
Positron Emission Tomography ◽  
Clinical Practice ◽  
Fdg Pet ◽  
Emission Tomography ◽  
Positron Emission ◽  
Pet Ct ◽  
Fdg Pet Ct

The utility of positron emission tomography (PET) for the evaluation of response to immunotherapy has been considered a hot topic, particularly in the last 2 to 3 years. Different experiences have been collected in clinical practice, with 18F-Fluorodeoxyglucose (FDG) PET/computed tomography (CT), particularly in patients affected by lymphoma, malignant melanoma, and lung cancer. It has been tested in different settings of disease, from the prediction to the prognosis relative to the response to immunotherapy. In the present mini-review, some evidence is reported about the role of FDG PET/CT in patient candidates to or treated with immunotherapy.

Investigations with FDG-PET Scanning in Prostate Cancer Show Limited Value for Clinical Practice

2002 ◽  
Vol 41 (5) ◽  
pp. 425-429 ◽  
Author(s):  
Eeva Salminen ◽  
Annette Hogg ◽  
David Binns ◽  
Mark Frydenberg ◽  
Rodney Hicks
Keyword(s):  
Prostate Cancer ◽  
Clinical Practice ◽  
Fdg Pet ◽  
Pet Scanning

scholarly journals Role of Optimal Quantification of FDG PET Imaging in the Clinical Practice of Radiology

Radiographics ◽  
2016 ◽  
Vol 36 (2) ◽  
pp. 481-496 ◽  
Author(s):  
Pouya Ziai ◽  
Mohammad Reza Hayeri ◽  
Aliaksei Salei ◽  
Ali Salavati ◽  
Sina Houshmand ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Pet Imaging ◽  
Fdg Pet
Sign in / Sign up

Export Citation Format

Share Document